Abiopharma

News list

(10% Negative) Seagen Inc. (SGEN) Announces Delay in release Trials for its territory Due to Regulatory Process, Safety Review, Efficacy Assessment

Full text

News bot Oct. 1, 2025, 9:44 p.m.
📋 Seagen Inc. (SGEN) - Clinical Trial Update

Filing Date: 2022-05-23

Accepted: 2022-05-23 08:11:02

Event Type: Clinical Trial Update
Event Details:
Seagen Inc (was acquised by Pfizer Inc. (NYSE: PFE) on 14/12/2023) (SGEN) Announces Clinical Trial Update Seagen Inc (was acquised by Pfizer Inc. (NYSE: PFE) on 14/12/2023) (SGEN) provided an update on its clinical development programs. Clinical Development Highlights:
Drug Program: release, need
Diseases/Conditions: its territory
Clinical Stage: Clinical Trial, Phase 2
Update Type: Trial Timeline Adjustment
Primary Factors: Regulatory Process
Collaboration: Seagen Inc.
💼 Business Developments:
- Partnership: Not available
- Acquisition: Not available
- Licensing: Not available
- Regulatory Approval
- Executive Changes: Not available
Structured Data:
- Company Name: Seagen Inc (was acquised by Pfizer Inc. (NYSE: PFE) on 14/12/2023)
- CIK: 0001060736
- Ticker Symbol: SGEN
- Period End Date: 2022-05-23
- Document Type: 8-K